title: Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy.
abstract: Currently, there are 1.0 million annual hospital discharges for acute heart failure (AHF). The total cost of heart failure (HF) care in the United States is projected to increase to $53 billion in 2030, with the majority of costs (80 %) related to AHF hospitalizations. Approximately 50 % of AHF episodes occur in patients with preserved ejection fraction (HFpEF). There is a dearth of evidence-based guidelines for the management of AHF in HFpEF patients. Here, we briefly review the epidemiology, pathophysiology, and treatment of AHF patients with HFpEF.
authors.affiliation: Mayo Clinic Cardiovascular Research, Guggenheim 9, 200 First Street Southwest, Rochester, MN 55905, USA.
authors.forename: Kalkidan
authors.initials: K
authors.lastname: Bishu
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Redfield
mesh_terms: D000208:Acute Disease; D015415:Biomarkers / Q000097:blood; D006333:Heart Failure / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D011379:Prognosis; D013318:Stroke Volume / Q000502:physiology*; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D014665:Vasodilator Agents